Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542

Viral entry inhibitors represent an emerging mode of therapy for human immunodeficiency virus type 1 (HIV-1) infection. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates. PRO 542 binds to the viral surface glycoprotein...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Jacobson, Jeffrey M., Israel, Robert J., Lowy, Israel, Ostrow, Nancy A., Vassilatos, Linda S., Barish, Melanie, Tran, Diep N. H., Sullivan, Brian M., Ketas, Thomas J., O'Neill, Tobias J., Nagashima, Kirsten A., Huang, Wei, Petropoulos, Christos J., Moore, John P., Maddon, Paul J., Olson, William C.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2004
Assuntos:	Antiviral Agents
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC321533/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/14742190/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.2.423-429.2004
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!